Dystrophic Epidermolysis Bullosa Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Dystrophic Epidermolysis Bullosa remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 45 matched trial records and 19 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700966 | Prademagene zamikeracel | Not Applicable; Recruiting | Abeona Therapeutics, Inc. | United States | The number and incidence of treatment-related malignancies. (From enrollment to 15 years post-treatment); The number and incidence of treatment-emergent SAEs, including systematic and wound specific SAEs (From enrollment to 15 years post-treatment) | 2045-04-01 |
| NCT07684105 | Intervention not normalized | Not Applicable; Not yet recruiting | Centre Hospitalier Universitaire de Nice | France | overall patient satisfaction with the treatment (month 1); overall patient satisfaction with the treatment (month 3) | 2026-12-31 |
| NCT07596927 | Intervention not normalized | Phase 4; Active, not recruiting | Ceuma University | Brazil | Tissue Repair of Oral Vesiculobullous Lesions (Baseline (pre-treatment) and daily assessment for 7 days after completion of…) | 2026-01-23 |
| NCT07230223 | Mesenchymal Stem Cells Derived Exosomes(Isfahan University of Medical Sciences) | Phase 1/2; Recruiting | Isfahan University of Medical Sciences | Iran | Rate of wound closure (Day 14); EBDASI (Day 14, 28, month 3 and month 6) | 2025-12-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics (Phase 1/2): the indexed record reports Clinical Response = 5.0 Pts.
- Beremagene Geperpavec is the First FDA-Approved Topical Gene Therapy for Dystrophic Epidermolysis Bullosa (Phase 3): the indexed record reports AE = fever, pruritus, application site discharge, erythema, chills, and squamous cell carcinoma.; AE = fever, pruritus, application site discharge, erythema, chills, and squamous cell carcinoma..
- Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE) (Phase 3): the indexed record reports First complete closure of target wound(within 45 days) = 26.7 %; First complete closure of target wound(within 45 days) = 50.0 %; First complete closure of target wound(within 45 days) = 26.2 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Prademagene zamikeracel (Approved; COL7A1), Mesenchymal Stem Cells Derived Exosomes(Isfahan University of Medical Sciences) (Phase 1/2). Company & Deal Intelligence records identify sponsor context for Abeona Therapeutics, Inc. (ABEO), Centre Hospitalier Universitaire de Nice, Ceuma University, Isfahan University of Medical Sciences. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Dystrophic Epidermolysis Bullosa has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
